Cargando…
Diabetes and Cancer: Cancer Should Be Screened in Routine Diabetes Assessment
Cancer incidence appears to be increased in both type 1 and type 2 diabetes mellitus (DM). DM represents a risk factor for cancer, particularly hepatocellular, hepatobiliary, pancreas, breast, ovarian, endometrial, and gastrointestinal cancers. In addition, there is evidence showing that DM is assoc...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Diabetes Association
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6943263/ https://www.ncbi.nlm.nih.gov/pubmed/31902143 http://dx.doi.org/10.4093/dmj.2019.0177 |
_version_ | 1783484852476051456 |
---|---|
author | Suh, Sunghwan Kim, Kwang-Won |
author_facet | Suh, Sunghwan Kim, Kwang-Won |
author_sort | Suh, Sunghwan |
collection | PubMed |
description | Cancer incidence appears to be increased in both type 1 and type 2 diabetes mellitus (DM). DM represents a risk factor for cancer, particularly hepatocellular, hepatobiliary, pancreas, breast, ovarian, endometrial, and gastrointestinal cancers. In addition, there is evidence showing that DM is associated with increased cancer mortality. Common risk factors such as age, obesity, physical inactivity and smoking may contribute to increased cancer risk in patients with DM. Although the mechanistic process that may link diabetes to cancer is not completely understood yet, biological mechanisms linking DM and cancer are hyperglycemia, hyperinsulinemia, increased bioactivity of insulin-like growth factor 1, oxidative stress, dysregulations of sex hormones, and chronic inflammation. However, cancer screening rate is significantly lower in people with DM than that in people without diabetes. Evidence from previous studies suggests that some medications used to treat DM are associated with either increased or reduced risk of cancer. However, there is no strong evidence supporting the association between the use of anti-hyperglycemic medication and specific cancer. In conclusion, all patients with DM should be undergo recommended age- and sex appropriate cancer screenings to promote primary prevention and early detection. Furthermore, cancer should be screened in routine diabetes assessment. |
format | Online Article Text |
id | pubmed-6943263 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Korean Diabetes Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-69432632020-01-09 Diabetes and Cancer: Cancer Should Be Screened in Routine Diabetes Assessment Suh, Sunghwan Kim, Kwang-Won Diabetes Metab J Review Cancer incidence appears to be increased in both type 1 and type 2 diabetes mellitus (DM). DM represents a risk factor for cancer, particularly hepatocellular, hepatobiliary, pancreas, breast, ovarian, endometrial, and gastrointestinal cancers. In addition, there is evidence showing that DM is associated with increased cancer mortality. Common risk factors such as age, obesity, physical inactivity and smoking may contribute to increased cancer risk in patients with DM. Although the mechanistic process that may link diabetes to cancer is not completely understood yet, biological mechanisms linking DM and cancer are hyperglycemia, hyperinsulinemia, increased bioactivity of insulin-like growth factor 1, oxidative stress, dysregulations of sex hormones, and chronic inflammation. However, cancer screening rate is significantly lower in people with DM than that in people without diabetes. Evidence from previous studies suggests that some medications used to treat DM are associated with either increased or reduced risk of cancer. However, there is no strong evidence supporting the association between the use of anti-hyperglycemic medication and specific cancer. In conclusion, all patients with DM should be undergo recommended age- and sex appropriate cancer screenings to promote primary prevention and early detection. Furthermore, cancer should be screened in routine diabetes assessment. Korean Diabetes Association 2019-12 2019-12-23 /pmc/articles/PMC6943263/ /pubmed/31902143 http://dx.doi.org/10.4093/dmj.2019.0177 Text en Copyright © 2019 Korean Diabetes Association http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Suh, Sunghwan Kim, Kwang-Won Diabetes and Cancer: Cancer Should Be Screened in Routine Diabetes Assessment |
title | Diabetes and Cancer: Cancer Should Be Screened in Routine Diabetes Assessment |
title_full | Diabetes and Cancer: Cancer Should Be Screened in Routine Diabetes Assessment |
title_fullStr | Diabetes and Cancer: Cancer Should Be Screened in Routine Diabetes Assessment |
title_full_unstemmed | Diabetes and Cancer: Cancer Should Be Screened in Routine Diabetes Assessment |
title_short | Diabetes and Cancer: Cancer Should Be Screened in Routine Diabetes Assessment |
title_sort | diabetes and cancer: cancer should be screened in routine diabetes assessment |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6943263/ https://www.ncbi.nlm.nih.gov/pubmed/31902143 http://dx.doi.org/10.4093/dmj.2019.0177 |
work_keys_str_mv | AT suhsunghwan diabetesandcancercancershouldbescreenedinroutinediabetesassessment AT kimkwangwon diabetesandcancercancershouldbescreenedinroutinediabetesassessment |